A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer

Inclusion criteria

• Histologically or cytologically confirmed prostate adenocarcinoma without neuroendocrine or small cell features
• Presence of metastatic lesions confirmed by evaluable imaging examinations (per PCWG4, evaluable imaging examinations refer to examinations with definite lesion assessment criteria, including CT, MRI or bone scan).
• Has an ECOG PS 0-1.
• Has a life expectancy of ≥ 3 months.
• Has adequate organ function

Exclusion criteria

• With untreated local therapy (radiotherapy or surgery) or active central nervous system (CNS) tumor metastases. Participants with a history of leptomeningeal metastasis or current leptomeningeal metastasis.
• Patients with other malignant tumors within 5 years prior to the first study drug administration, excluding adequately treated basal cell carcinoma or squamous cell carcinoma.
• Those with uncontrolled tumor-related pain as judged by the investigator, who require analgesic medication.
• Having severe cardiovascular and cerebrovascular diseases
• Suffering from active severe digestive system diseases
• History of prior interstitial pneumonia
• Has active infection requiring systemic treatment.
• Adverse reactions from prior anti-tumor therapy have not recovered to CTCAE grade ≤1